DexCom (NASDAQ:DXCM) EVP Sells $142,868.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $142,868.00. Following the transaction, the executive vice president owned 99,885 shares of the company’s stock, valued at $8,394,335.40. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of DexCom stock opened at $89.35 on Friday. The company has a market cap of $33.72 billion, a PE ratio of 35.32, a price-to-earnings-growth ratio of 1.47 and a beta of 1.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The business has a 50 day moving average price of $84.10 and a 200-day moving average price of $73.28. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Plato Investment Management Ltd purchased a new stake in shares of DexCom during the 2nd quarter worth approximately $782,000. Aurora Investment Counsel purchased a new position in DexCom in the second quarter valued at approximately $2,340,000. E Fund Management Co. Ltd. purchased a new position in DexCom in the second quarter valued at approximately $1,273,000. Silvant Capital Management LLC bought a new position in DexCom during the second quarter valued at $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in DexCom during the second quarter valued at $89,940,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of analyst reports. Argus lifted their price objective on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price for the company. Wells Fargo & Company raised their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada increased their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $89.08.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.